Histone deacetylase inhibitors as therapeutics for polyglutamine disorders (original) (raw)

• Bates, G. P., Harper, P. S. & Jones, A. L. (eds) Huntington's Disease (Oxford Univ. Press, Oxford, 2002).
  Google Scholar
• Cummings, C. J. & Zoghbi, H. Y. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum. Mol. Genet. 9, 909–916 (2000).
  CAS PubMed Google Scholar
• Paulson, H. L. et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19, 333–344 (1997).
  CAS PubMed Google Scholar
• Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537–548 (1997).
  CAS PubMed Google Scholar
• DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990–1993 (1997).
  CAS PubMed Google Scholar
• Wacker, J. L., Zareie, M. H., Fong, H., Sarikaya, M. & Muchowski, P. J. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nature Struct. Mol. Biol. 11, 1215–1222 (2004).
  CAS Google Scholar
• Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805–810 (2004).
  CAS PubMed Google Scholar
• Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D. & Housman, D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl Acad. Sci. USA 96, 11404–11409 (1999).
  CAS PubMed PubMed Central Google Scholar
• Perez, M. K. et al. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell Biol. 143, 1457–1470 (1998).
  CAS PubMed PubMed Central Google Scholar
• Cha, J. -H. J. et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl Acad. Sci. USA 95, 6480–6485 (1998). The first study to show abnormal transcriptional regulation in HD.
  CAS PubMed PubMed Central Google Scholar
• Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19, 1176–1179 (2000).
  CAS PubMed PubMed Central Google Scholar
• Glozak, M. A., Sengupta, N., Zhang, X. & Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15–23 (2005).
  CAS PubMed Google Scholar
• Norton, V., Marvin, K., Yau, P. & Bradbury, E. Nucleosome linking number change controlled by acetylation of histones H3 and H4. J. Biol. Chem. 265, 19848–19852 (1990).
  CAS PubMed Google Scholar
• Lee, D. Y., Hayes, J. J., Pruss, D. & Wolffe, A. P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72, 73–84 (1993).
  CAS PubMed Google Scholar
• Hebbes, T. R., Thorne, A. W., Crane-Robinson C. A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J. 7, 1395–1402 (1988).
  CAS PubMed PubMed Central Google Scholar
• Rundlett, S. E. et al. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc. Natl Acad. Sci. USA 93, 14503–14508 (1996).
  CAS PubMed PubMed Central Google Scholar
• Zhu, W. G., Lakshmanan, R. R., Beal, M. D. & Otterson, G. A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61, 1327–1333 (2001).
  CAS PubMed Google Scholar
• Marks, P. A., Richon, V. M. & Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92, 1210–1216 (2000).
  CAS PubMed Google Scholar
• Glaser, K. B. et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151–163 (2003).
  CAS PubMed Google Scholar
• Mariadason, J. M., Corner, G. A. & Augenlicht, L. H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60, 4561–4572 (2000).
  CAS PubMed Google Scholar
• Chambers, A. E. et al. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur. J. Cancer 39, 1165–1175 (2003).
  CAS PubMed Google Scholar
• Cress, W. D. & Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184, 1–16 (2000).
  CAS PubMed Google Scholar
• Timmermann, S., Lehrmann, H., Polesskaya, A. & Harel-Bellan, A. Histone acetylation and disease. Cell. Mol. Life. Sci. 58, 728–736 (2001).
  CAS PubMed Google Scholar
• Hughes, R. E. Polyglutamine disease: acetyltransferases awry. Curr. Biol. 12, R141–R143 (2002).
  CAS PubMed Google Scholar
• Yang, X. -J. & Gregoire, S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol. Cell. Biol. 25, 2873–2884 (2005).
  CAS PubMed PubMed Central Google Scholar
• de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S. & van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737–749 (2003). A comprehensive review of the different classes of HDAC.
  CAS PubMed PubMed Central Google Scholar
• Taunton, J., Hassig, C. A. & Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408–411 (1996).
  CAS PubMed Google Scholar
• Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188–193 (1999).
  CAS PubMed Google Scholar
• Longworth, M. S. & Laimins, L. A. Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene 25, 4495–4500 (2006).
  CAS PubMed Google Scholar
• Ayer, D. E. Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell Biol. 9, 193–198 (1999).
  CAS PubMed Google Scholar
• Carmen, A. A., Rundlett, S. E. & Grunstein, M. HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex. J. Biol. Chem. 271, 15837–15844 (1996).
  CAS PubMed Google Scholar
• Huang, E. Y. et al. Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev. 14, 45–54 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kao, H. Y., Downes, M., Ordentlich, P. & Evans, R. M. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev 14, 55–66 (2000).
  CAS PubMed PubMed Central Google Scholar
• Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45–57 (2002). An important study showing HDAC3-dependent activity of class II HDACs.
  CAS PubMed Google Scholar
• Seigneurin-Berny, D. et al. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol. Cell. Biol. 21, 8035–8044 (2001).
  CAS PubMed PubMed Central Google Scholar
• Zhang, Y. et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22, 1168–1179 (2003).
  CAS PubMed PubMed Central Google Scholar
• Fischer, D. D. et al. Isolation and characterization of a novel class II histone deacetylase, HDAC10. J. Biol. Chem. 277, 6656–6666 (2002).
  CAS PubMed Google Scholar
• Guardiola, A. R. & Yao, T. P. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem. 277, 3350–3356 (2002).
  CAS PubMed Google Scholar
• Kao, H. Y., Lee, C. H., Komarov, A., Han, C. C. & Evans, R. M. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. 277, 187–193 (2002).
  CAS PubMed Google Scholar
• Tong, J. J., Liu, J., Bertos, N. R. & Yang, X. J. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res. 30, 1114–1123 (2002).
  CAS PubMed PubMed Central Google Scholar
• Frye, R. A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273, 793–798 (2000).
  CAS PubMed Google Scholar
• Kaeberlein, M., McVey, M. & Guarente, L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 13, 2570–2580 (1999).
  CAS PubMed PubMed Central Google Scholar
• Denu, J. M. Linking chromatin function with metabolic networks: Sir2 family of NAD+-dependent deacetylases. Trends Biochem. Sci. 28, 41–48 (2003).
  CAS PubMed Google Scholar
• Sauve, A. A. et al. Chemistry of gene silencing: the mechanism of NAD+-dependent deacetylation reactions. Biochemistry 40, 15456–15463 (2001).
  CAS PubMed Google Scholar
• Sauve, A. A. & Schramm, V. L. SIR2: the biochemical mechanism of NAD+-dependent protein deacetylation and ADP-ribosyl enzyme intermediates. Curr. Med. Chem. 11, 807–826 (2004).
  CAS PubMed Google Scholar
• Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M. & Sinclair, D. A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277, 45099–45107 (2002).
  CAS PubMed Google Scholar
• Anekonda, T. S. & Reddy, P. H. Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem. 96, 305–313 (2006).
  CAS PubMed Google Scholar
• Gao, L., Cueto, M. A., Asselbergs, F. & Atadja, P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277, 25748–25755 (2002).
  CAS PubMed Google Scholar
• Bertos, N. R., Wang, A. H. & Yang, X. J. Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol. 79, 243–252 (2001).
  CAS PubMed Google Scholar
• Sengupta, N. & Seto, E. Regulation of histone deacetylase activities. J. Cell. Biochem. 93, 57–67 (2004).
  CAS PubMed Google Scholar
• McKinsey, T. A., Zhang, C. L. & Olson, E. N. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol. Cell. Biol. 21, 6312–6321 (2001).
  CAS PubMed PubMed Central Google Scholar
• Yang, W. M., Tsai, S. C., Wen, Y. D., Fejer, G. & Seto, E. Functional domains of histone deacetylase-3. J. Biol. Chem. 277, 9447–9454 (2002).
  CAS PubMed Google Scholar
• Lu, J., McKinsey, T. A., Nicol, R. L. & Olson, E. N. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc. Natl Acad. Sci. USA 97, 4070–4075 (2000).
  CAS PubMed PubMed Central Google Scholar
• Miska, E. A. et al. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J. 18, 5099–5107 (1999).
  CAS PubMed PubMed Central Google Scholar
• Mao, Z., Bonni, A., Xia, F., Nadal-Vicens, M. & Greenberg, M. E. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286, 785–790 (1999).
  CAS PubMed Google Scholar
• Gaudilliere, B., Shi, Y. & Bonni, A. RNA Interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival. J. Biol. Chem. 277, 46442–46446 (2002).
  CAS PubMed Google Scholar
• Miska, E. A. et al. Differential localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res. 29, 3439–3447 (2001).
  CAS PubMed PubMed Central Google Scholar
• Kao, H. Y. et al. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J. Biol. Chem. 276, 47496–47507 (2001).
  CAS PubMed Google Scholar
• Grozinger, C. M. & Schreiber, S. L. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl Acad. Sci. USA 97, 7835–7840 (2000).
  CAS PubMed PubMed Central Google Scholar
• Bolger, T. A. & Yao, T. P. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J. Neurosci. 25, 9544–9553 (2005).
  CAS PubMed PubMed Central Google Scholar
• Chawla, S., Vanhoutte, P., Arnold, F. J., Huang, C. L. & Bading, H. Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J. Neurochem. 85, 151–159 (2003).
  CAS PubMed Google Scholar
• Deckel, A. W., Elder, R. & Fuhrer, G. Biphasic developmental changes in Ca2+/calmodulin-dependent proteins in R6/2 Huntington's disease mice. Neuroreport 13, 707–711 (2002).
  CAS PubMed Google Scholar
• Hoshino, M. et al. Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein. J. Neurochem. 87, 257–267 (2003).
  CAS PubMed Google Scholar
• Sakamoto, J., Miura, T., Shimamoto, K. & Horio, Y. Predominant expression of Sir2α, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett. 556, 281–286 (2004).
  CAS PubMed Google Scholar
• Hisahara, S., Chiba, S., Matsumoto, H. & Horio, Y. Transcriptional regulation of neuronal genes and its effect on neural functions: NAD-dependent histone deacetylase SIRT1 (Sir2α). J. Pharmacol. Sci. 98, 200–204 (2005).
  CAS PubMed Google Scholar
• Cha, J. -H. J. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23, 387–392 (2000).
  CAS PubMed Google Scholar
• Luthi-Carter, R. et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11, 1911–1926 (2002).
  CAS PubMed Google Scholar
• Luthi-Carter, R. et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11, 1927–1937 (2002).
  CAS PubMed Google Scholar
• Hodges, A. et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15, 965–977 (2006). The above three papers contain important microarray expression profile information about HD and DRPLA.
  CAS PubMed Google Scholar
• Steffan, J. S. et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97, 6763–6768 (2000). The first paper to implicate aberrant interactions between CBP and HTT in transcriptional repression in HD.
  CAS PubMed PubMed Central Google Scholar
• Nucifora, F. C. Jr et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423–2428 (2001). Highlights the implications of CBP in the pathogenic mechanism of polyglutamine repeat disease.
  CAS PubMed Google Scholar
• McCampbell, A. et al. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9, 2197–2202 (2000).
  CAS PubMed Google Scholar
• McCampbell, A. & Fischbeck, K. H. Polyglutamine and CBP: fatal attraction? Nature Med. 7, 528–530 (2001).
  CAS PubMed Google Scholar
• Dunah, A. W. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238–2243 (2002).
  CAS PubMed Google Scholar
• van Roon-Mom, W. M. et al. Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Brain Res. Mol. Brain Res. 109, 1–10 (2002).
  CAS PubMed Google Scholar
• Igarashi, S. et al. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 14, 565–568 (2003).
  CAS PubMed Google Scholar
• Hazeki, N. et al. Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine. Biochem. Biophys. Res. Commun. 294, 429–440 (2002).
  CAS PubMed Google Scholar
• Mori, N., Schoenherr, C., Vandenbergh, D. J. & Anderson, D. J. A common silencer element in the SCG10 and type II Na+ channel genes binds a factor present in nonneuronal cells but not in neuronal cells. Neuron 9, 45–54 (1992).
  CAS PubMed Google Scholar
• Schoenherr, C. J., Paquette, A. J. & Anderson, D. J. Identification of potential target genes for the neuron-restrictive silencer factor. Proc. Natl Acad. Sci. USA 93, 9881–9886 (1996).
  CAS PubMed PubMed Central Google Scholar
• Chen, Z. -F., Paquette, A. J. & Anderson, D. J. NRSF/REST is required in vivo for repression of multiple neuronal target genes during embryogenesis. Nature Genet. 20, 136–142 (1998).
  CAS PubMed Google Scholar
• Zuccato, C. et al. Loss of huntingtin-mediated BDNF gene transcription in huntington's disease. Science 293, 493–498 (2001).
  CAS PubMed Google Scholar
• Zuccato, C. et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. 35, 76–83 (2003).
• Bates, E. A., Victor, M., Jones, A. K., Shi, Y. & Hart, A. C. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 26, 2830–2838 (2006).
  CAS PubMed PubMed Central Google Scholar
• Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455–458 (2002).
  CAS PubMed Google Scholar
• Bali, P. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729–26734 (2005).
  CAS PubMed Google Scholar
• Kovacs, J. J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601–607 (2005).
  CAS PubMed Google Scholar
• Hook, S. S., Orian, A., Cowley, S. M. & Eisenman, R. N. Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Proc. Natl Acad. Sci. USA 99, 13425–13430 (2002).
  CAS PubMed PubMed Central Google Scholar
• Hideshima, T. et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl Acad. Sci. USA 102, 8567–8572 (2005).
  CAS PubMed PubMed Central Google Scholar
• Iwata, A., Riley, B. E., Johnston, J. A. & Kopito, R. R. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 280, 40282–40292 (2005).
  CAS PubMed Google Scholar
• Kawaguchi, Y. et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727–738 (2003).
  CAS PubMed Google Scholar
• Grubisha, O., Smith, B. C. & Denu, J. M. Small molecule regulation of Sir2 protein deacetylases. FEBS J. 272, 4607–4616 (2005).
  CAS PubMed Google Scholar
• Ghosh, S. & Feany, M. B. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Hum. Mol. Genet. 13, 2011–2018 (2004).
  CAS PubMed Google Scholar
• Parker, J. A. et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nature Genet. 37, 349–350 (2005).
  CAS PubMed Google Scholar
• Sinclair, D. Sirtuins for healthy neurons. Nature Genet. 37, 339–340 (2005).
  CAS PubMed Google Scholar
• Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997).
  CAS PubMed Google Scholar
• Hughes, P. E., Alexi, T. & Schreiber, S. S. A role for the tumour suppressor gene p53 in regulating neuronal apoptosis. Neuroreport 8, v–xii (1997).
  CAS PubMed Google Scholar
• Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595–606 (1997).
  CAS PubMed Google Scholar
• Ito, A. et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21, 6236–6245 (2002).
  CAS PubMed PubMed Central Google Scholar
• Gang Liu, X. C. Regulation of the p53 transcriptional activity. J. Cell. Biochem. 97, 448–458 (2006).
  PubMed Google Scholar
• Luo, J. et al. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl Acad. Sci. USA 101, 2259–2264 (2004).
  CAS PubMed PubMed Central Google Scholar
• Bae, B. I. et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29–41 (2005).
  CAS PubMed Google Scholar
• Feng, D. & Kan, Y. W. The binding of the ubiquitous transcription factor Sp1 at the locus control region represses the expression of β-like globin genes. Proc. Natl Acad. Sci. USA 102, 9896–9900 (2005).
  CAS PubMed PubMed Central Google Scholar
• Murphy, M. et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13, 2490–2501 (1999).
  CAS PubMed PubMed Central Google Scholar
• Luo, J., Su, F., Chen, D., Shiloh, A. & Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408, 377–381 (2000).
  CAS PubMed Google Scholar
• Juan, L. J. et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275, 20436–20443 (2000).
  CAS PubMed Google Scholar
• Pratt, W. B. & Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood) 228, 111–133 (2003).
  CAS Google Scholar
• Bagatell, R. et al. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin. Cancer Res. 7, 2076–2084 (2001).
  CAS PubMed Google Scholar
• Neckers, L. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin. Cancer Res. 8, 962–966 (2002).
  CAS PubMed Google Scholar
• Waza, M. et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nature Med. 11, 1088–1095 (2005).
  CAS PubMed Google Scholar
• Aoyagi, S. & Archer, T. K. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol. 15, 565–567 (2005).
  CAS PubMed Google Scholar
• Chen, L. et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol. Cancer Ther. 4, 1311–1319 (2005).
  CAS PubMed Google Scholar
• Ren, M., Leng, Y., Jeong, M., Leeds, P. R. & Chuang, D. M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89, 1358–1367 (2004).
  CAS PubMed Google Scholar
• Zhao, Y. et al. Lifespan extension and elevated hsp gene expression in Drosophila caused by histone deacetylase inhibitors. J. Exp. Biol. 208, 697–705 (2005).
  CAS PubMed Google Scholar
• Hay, D. G. et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13, 1389–1405 (2004).
  CAS PubMed Google Scholar
• Woodman, B. et al. The HdhQ150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. (in the press).
• Li, F., Macfarlan, T., Pittman, R. N. & Chakravarti, D. Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J. Biol. Chem. 277, 45004–45012 (2002).
  CAS PubMed Google Scholar
• Gatchel, J. R. & Zoghbi, H. Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nature Rev. Genet. 6, 743–755 (2005).
  CAS PubMed Google Scholar
• Tsai, C. C. et al. Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc. Natl Acad. Sci. USA 101, 4047–4052 (2004).
  CAS PubMed PubMed Central Google Scholar
• Matilla, A. et al. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 389, 974–978 (1997).
  CAS PubMed Google Scholar
• Seo, S. et al. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 104, 119–130 (2001).
  CAS PubMed Google Scholar
• Chen, H. K. et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113, 457–468 (2003).
  CAS PubMed Google Scholar
• Burnett, B., Li, F. & Pittman, R. N. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 12, 3195–3205 (2003).
  CAS PubMed Google Scholar
• Burnett, B. G. & Pittman, R. N. The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc. Natl Acad. Sci. USA 102, 4330–4335 (2005).
  CAS PubMed PubMed Central Google Scholar
• Palhan, V. B. et al. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc. Natl Acad. Sci. USA 102, 8472–8477 (2005).
  CAS PubMed PubMed Central Google Scholar
• McMahon, S. J., Pray-Grant, M. G., Schieltz, D., Yates, J. R. & Grant, P. A. Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. Proc. Natl Acad. Sci. USA 102, 8478–8482 (2005).
  CAS PubMed PubMed Central Google Scholar
• Sterner, D. E., Belotserkovskaya, R. & Berger, S. L. SALSA, a variant of yeast SAGA, contains truncated Spt7, which correlates with activated transcription. Proc. Natl Acad. Sci. USA 99, 11622–11627 (2002).
  CAS PubMed PubMed Central Google Scholar
• Pray-Grant, M. G. et al. The novel SLIK histone acetyltransferase complex functions in the yeast retrograde response pathway. Mol. Cell. Biol. 22, 8774–8786 (2002).
  CAS PubMed PubMed Central Google Scholar
• Helmlinger, D. et al. Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 4, e67 (2006).
  PubMed PubMed Central Google Scholar
• Schilling, G. et al. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 24, 275–286 (1999).
  CAS PubMed Google Scholar
• Wood, J. D. et al. Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription. J. Cell Biol. 150, 939–948 (2000).
  CAS PubMed PubMed Central Google Scholar
• Gelmetti, V. et al. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol. 18, 7185–7191 (1998).
  CAS PubMed PubMed Central Google Scholar
• Lutterbach, B. et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol. Cell. Biol. 18, 7176–7184 (1998).
  CAS PubMed PubMed Central Google Scholar
• Wang, J., Hoshino, T., Redner, R. L., Kajigaya, S. & Liu, J. M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl Acad. Sci. USA 95, 10860–10865 (1998).
  CAS PubMed PubMed Central Google Scholar
• Ying, M. et al. Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J. Biol. Chem. 281, 12580–12586 (2006).
  CAS PubMed Google Scholar
• Wang, L., Rajan, H., Pitman, J. L., McKeown, M. & Tsai, C. -C. Histone deacetylase-associating Atrophin proteins are nuclear receptor corepressors. Genes Dev. 20, 525–530 (2006).
  PubMed PubMed Central Google Scholar
• McCampbell, A. et al. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl Acad. Sci. USA 98, 15179–15184 (2001).
  CAS PubMed PubMed Central Google Scholar
• Steffan, J. S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739–743 (2001). The first study in Drosophila to show HDAC inhibitors as a beneficial therapy for polyglutamine repeat disease.
  CAS PubMed Google Scholar
• Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041–2046 (2003). The first published study of the use of an HDAC inhibitor as a therapeutic agent in a mouse model of HD.
  CAS PubMed PubMed Central Google Scholar
• Ferrante, R. J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418–9427 (2003).
  CAS PubMed PubMed Central Google Scholar
• Gardian, G. et al. Neuroprotective effects of phenylbutyrate in the N171–82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280, 556–563 (2005).
  CAS PubMed Google Scholar
• Drummond, D. C. et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495–528 (2005).
  CAS PubMed Google Scholar
• Miller, T. A., Witter, D. J. & Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 46, 5097–5116 (2003).
  CAS PubMed Google Scholar
• Grozinger, C. M. & Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 9, 3–16 (2002).
  CAS PubMed Google Scholar
• Vannini, A. et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101, 15064–15069 (2004).
  CAS PubMed PubMed Central Google Scholar
• Minamiyama, M. et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 13, 1183–1192 (2004).
  CAS PubMed Google Scholar
• Borovecki, F. et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl Acad. Sci. USA 102, 11023–11028 (2005).
  CAS PubMed PubMed Central Google Scholar
• Agrawal, N. et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl Acad. Sci. USA 102, 3777–3781 (2005).
  CAS PubMed PubMed Central Google Scholar
• Byers, R. K. & Banker, B. Q. Infantile muscular atrophy. Arch. Neurol. 5, 140–164 (1961).
  CAS PubMed Google Scholar
• Brzustowicz, L. M. et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2–13.3. Nature 344, 540–541 (1990).
  CAS PubMed Google Scholar
• Melki, J. et al. Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature 344, 767–768 (1990).
  CAS PubMed Google Scholar
• Gilliam, T. C. et al. Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature 345, 823–825 (1990).
  CAS PubMed Google Scholar
• Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nature Genet. 16, 265–269 (1997).
  CAS PubMed Google Scholar
• Iannaccone, S. T., Smith, S. A. & Simard, L. R. Spinal muscular atrophy. Curr. Neurol. Neurosci. Rep. 4, 74–80 (2004).
  PubMed Google Scholar
• Chang, J. G. et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl Acad. Sci. USA 98, 9808–9813 (2001).
  CAS PubMed PubMed Central Google Scholar
• Sumner, C. J. et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54, 647–654 (2003).
  CAS PubMed Google Scholar
• Brichta, L. et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 12, 2481–2489 (2003).
  CAS PubMed Google Scholar
• Andreassi, C. et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 12, 59–65 (2004).
  CAS PubMed Google Scholar
• Riessland, M. Brichta, L., Hahnen, E. & Wirth, B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. 1–10 (2006).
• Kernochan, L. E. et al. The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 14, 1171–1182 (2005).
  CAS PubMed Google Scholar
• Jung, M. et al. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 42, 4669–4679 (1999).
  CAS PubMed Google Scholar
• Furumai, R. et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl Acad. Sci. USA 98, 87–92 (2001).
  CAS PubMed Google Scholar
• Roopra, A. et al. Transcriptional repression by neuron-restrictive silencer factor is mediated via the Sin3-histone deacetylase complex. Mol. Cell. Biol. 20, 2147–2157 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kao, H. Y. et al. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev. 12, 2269–2277 (1998).
  CAS PubMed PubMed Central Google Scholar
• Zhang, Y. et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13, 1924–1935 (1999).
  CAS PubMed PubMed Central Google Scholar
• Amann, J. M. et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21, 6470–6483 (2001).
  CAS PubMed PubMed Central Google Scholar
• Wen, Y. D. et al. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl Acad. Sci. USA 97, 7202–7207 (2000).
  CAS PubMed PubMed Central Google Scholar
• Li, J. et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19, 4342–4350 (2000).
  CAS PubMed PubMed Central Google Scholar
• Grozinger, C. M., Hassig, C. A. & Schreiber, S. L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. PNAS 96, 4868–4873 (1999).
  CAS PubMed PubMed Central Google Scholar
• Waltregny, D. et al. Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J. 19, 966–998 (2005).
  CAS PubMed Google Scholar
• Lemercier, C. et al. mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity. J. Biol. Chem. 275, 15594–15599 (2000).
  CAS PubMed Google Scholar
• Huntington's Disease Collaborative Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971–983 (1993).
• Spada, A. R. L., Wilson, E. M., Lubahn, D. B., Harding, A. E. & Fischbeck, K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77–79 (1991).
  PubMed Google Scholar
• Koide, R. et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nature Genet. 6, 9–13 (1994).
  CAS PubMed Google Scholar
• Nagafuchi, S. et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nature Genet. 6, 14–18 (1994).
  CAS PubMed Google Scholar
• Orr, H. T. et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nature Genet. 4, 221–226 (1993).
  CAS PubMed Google Scholar
• Matilla, T. et al. Presymptomatic analysis of spinocerebellar ataxia type 1 (SCA1) via the expansion of the SCA1 CAG-repeat in a large pedigree displaying anticipation and parental male bias. Hum. Mol. Genet. 2, 2123–2128 (1993).
  CAS PubMed Google Scholar
• Imbert, G. et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nature Genet. 14, 285–291 (1996).
  CAS PubMed Google Scholar
• Sanpei, K. et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nature Genet. 14, 277–284 (1996).
  CAS PubMed Google Scholar
• Pulst, S. -M. et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nature Genet. 14, 269–276 (1996).
  CAS PubMed Google Scholar
• Kawaguchi, Y. et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. 8, Nature Genet. 221–228 (1994).
  CAS PubMed Google Scholar
• Zhuchenko, O. et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel. Nature Genet. 15, 62–69 (1997).
  CAS PubMed Google Scholar
• David, G. et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nature Genet. 17, 65–70 (1997).
  CAS PubMed Google Scholar
• Lindblad, K. et al. An expanded CAG repeat sequence in spinocerebellar ataxia type 7. Genome Res. 6, 965–971 (1996).
  CAS PubMed Google Scholar
• Koide, R. et al. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum. Mol. Genet. 8, 2047–2053 (1999).
  CAS PubMed Google Scholar
• Schaffar, G. et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 15, 95–105 (2004).
  CAS PubMed Google Scholar